Literature DB >> 17244400

Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence.

Anthony Culyer1, Christopher McCabe, Andrew Briggs, Karl Claxton, Martin Buxton, Ron Akehurst, Mark Sculpher, John Brazier.   

Abstract

There has been much speculation about whether the National Institute for Health and Clinical Excellence (NICE) has, or ought to have, a 'threshold' figure for the cost of an additional quality-adjusted life-year above which a technology will not be recommended for use. We argue that it is not constitutionally appropriate for NICE to set such a threshold, which is properly the business of parliament. Instead, the task for NICE is as a 'threshold-searcher' - to seek to identify an optimal threshold incremental cost-effectiveness ratio, at the ruling rate of expenditure, that is consistent with the aim of the health service to maximize population health. This will involve the identification of technologies currently made available by the National Health Service that have incremental cost-effectiveness ratios above the threshold, and alternative uses for those resources in the shape of technologies not currently provided that fall below the threshold.

Entities:  

Mesh:

Year:  2007        PMID: 17244400     DOI: 10.1258/135581907779497567

Source DB:  PubMed          Journal:  J Health Serv Res Policy        ISSN: 1355-8196


  42 in total

1.  Real economics needs to reflect real decisions: a response to Johnson.

Authors:  Mark Sculpher; Karl Claxton
Journal:  Pharmacoeconomics       Date:  2012-02-01       Impact factor: 4.981

2.  Perspective and desire in comparative effectiveness research: the relative unimportance of mere preferences, the central importance of context.

Authors:  Anthony J Culyer
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

3.  Cost-effectiveness analysis and efficient use of the pharmaceutical budget: the key role of clinical pharmacologists.

Authors:  Richard Edlin; Jeff Round; Claire Hulme; Christopher McCabe
Journal:  Br J Clin Pharmacol       Date:  2010-09       Impact factor: 4.335

4.  Costs and benefits of free medications after myocardial infarction.

Authors:  Irfan A Dhalla; Monique A Smith; Niteesh K Choudhry; Avram E Denburg
Journal:  Healthc Policy       Date:  2009-11

5.  Exploring a new method for deriving the monetary value of a QALY.

Authors:  Carl Tilling; Marieke Krol; Arthur E Attema; Aki Tsuchiya; John Brazier; Job van Exel; Werner Brouwer
Journal:  Eur J Health Econ       Date:  2015-08-20

6.  Should the Lambda (λ) Remain Silent?

Authors:  Hossein Haji Ali Afzali; Jonathan Karnon; Mark Sculpher
Journal:  Pharmacoeconomics       Date:  2016-04       Impact factor: 4.981

Review 7.  Economic evaluation and decision making in the UK.

Authors:  Martin J Buxton
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 8.  Pharmacoeconomics and pharmacoepidemiology: curious bedfellows or a match made in heaven?

Authors:  Andrew H Briggs; Adrian R Levy
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

9.  Value based pricing for NHS drugs: an opportunity not to be missed?

Authors:  Karl Claxton; Andrew Briggs; Martin J Buxton; Anthony J Culyer; Christopher McCabe; Simon Walker; Mark J Sculpher
Journal:  BMJ       Date:  2008-02-02

10.  Value of information and pricing new healthcare interventions.

Authors:  Andrew R Willan; Simon Eckermann
Journal:  Pharmacoeconomics       Date:  2012-06-01       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.